BIOA Quote, Financials, Valuation and Earnings

Iovance Biotherapeutics, Inc. has a net margin of -982.04% compared to BioAge Labs, Inc.'s net margin of -135.28%. BioAge Labs, Inc.'s return on equity of -24.89% beat Iovance Biotherapeutics, Inc.'s return on equity of -54.43%.

BioAge Labs, Inc. has a consensus price target of $15.67, signalling downside risk potential of -19.95%. On the other hand Iovance Biotherapeutics, Inc. has an analysts' consensus of $9.11 which suggests that it could grow by 254.52%. Given that Iovance Biotherapeutics, Inc. has higher upside potential than BioAge Labs, Inc., analysts believe Iovance Biotherapeutics, Inc. is more attractive than BioAge Labs, Inc..

BioAge Labs, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Iovance Biotherapeutics, Inc. has a beta of 0.765, suggesting its less volatile than the S&P 500 by 23.531%.

BioAge Labs, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Iovance Biotherapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioAge Labs, Inc. pays -- of its earnings as a dividend. Iovance Biotherapeutics, Inc. pays out -- of its earnings as a dividend.

BioAge Labs, Inc. quarterly revenues are $2.1M, which are smaller than Iovance Biotherapeutics, Inc. quarterly revenues of $67.5M. BioAge Labs, Inc.'s net income of -$20.2M is higher than Iovance Biotherapeutics, Inc.'s net income of -$91.3M. Notably, BioAge Labs, Inc.'s price-to-earnings ratio is -- while Iovance Biotherapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioAge Labs, Inc. is 118.57x versus 3.40x for Iovance Biotherapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly & Co. has a net margin of -982.04% compared to BioAge Labs, Inc.'s net margin of 34.4%. BioAge Labs, Inc.'s return on equity of -24.89% beat Eli Lilly & Co.'s return on equity of 104.39%.

BioAge Labs, Inc. has a consensus price target of $15.67, signalling downside risk potential of -19.95%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,201.63 which suggests that it could grow by 15.54%. Given that Eli Lilly & Co. has higher upside potential than BioAge Labs, Inc., analysts believe Eli Lilly & Co. is more attractive than BioAge Labs, Inc..

BioAge Labs, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.388, suggesting its less volatile than the S&P 500 by 61.171%.

BioAge Labs, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly & Co. offers a yield of 0.6% to investors and pays a quarterly dividend of $1.73 per share. BioAge Labs, Inc. pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 26.14% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

BioAge Labs, Inc. quarterly revenues are $2.1M, which are smaller than Eli Lilly & Co. quarterly revenues of $19.3B. BioAge Labs, Inc.'s net income of -$20.2M is lower than Eli Lilly & Co.'s net income of $6.6B. Notably, BioAge Labs, Inc.'s price-to-earnings ratio is -- while Eli Lilly & Co.'s PE ratio is 46.04x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioAge Labs, Inc. is 118.57x versus 14.54x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.

Protokinetix, Inc. has a net margin of -982.04% compared to BioAge Labs, Inc.'s net margin of --. BioAge Labs, Inc.'s return on equity of -24.89% beat Protokinetix, Inc.'s return on equity of -111.59%.

BioAge Labs, Inc. has a consensus price target of $15.67, signalling downside risk potential of -19.95%. On the other hand Protokinetix, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that BioAge Labs, Inc. has higher upside potential than Protokinetix, Inc., analysts believe BioAge Labs, Inc. is more attractive than Protokinetix, Inc..

BioAge Labs, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Protokinetix, Inc. has a beta of 0.614, suggesting its less volatile than the S&P 500 by 38.569%.

BioAge Labs, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protokinetix, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioAge Labs, Inc. pays -- of its earnings as a dividend. Protokinetix, Inc. pays out -- of its earnings as a dividend.

BioAge Labs, Inc. quarterly revenues are $2.1M, which are larger than Protokinetix, Inc. quarterly revenues of --. BioAge Labs, Inc.'s net income of -$20.2M is lower than Protokinetix, Inc.'s net income of -$84.9K. Notably, BioAge Labs, Inc.'s price-to-earnings ratio is -- while Protokinetix, Inc.'s PE ratio is 23.85x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioAge Labs, Inc. is 118.57x versus -- for Protokinetix, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Plus Therapeutics, Inc. has a net margin of -982.04% compared to BioAge Labs, Inc.'s net margin of -316.61%. BioAge Labs, Inc.'s return on equity of -24.89% beat Plus Therapeutics, Inc.'s return on equity of --.

BioAge Labs, Inc. has a consensus price target of $15.67, signalling downside risk potential of -19.95%. On the other hand Plus Therapeutics, Inc. has an analysts' consensus of $5.50 which suggests that it could grow by 1898.55%. Given that Plus Therapeutics, Inc. has higher upside potential than BioAge Labs, Inc., analysts believe Plus Therapeutics, Inc. is more attractive than BioAge Labs, Inc..

BioAge Labs, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Plus Therapeutics, Inc. has a beta of 0.886, suggesting its less volatile than the S&P 500 by 11.364%.

BioAge Labs, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Plus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioAge Labs, Inc. pays -- of its earnings as a dividend. Plus Therapeutics, Inc. pays out -- of its earnings as a dividend.

BioAge Labs, Inc. quarterly revenues are $2.1M, which are larger than Plus Therapeutics, Inc. quarterly revenues of $1.4M. BioAge Labs, Inc.'s net income of -$20.2M is lower than Plus Therapeutics, Inc.'s net income of -$4.4M. Notably, BioAge Labs, Inc.'s price-to-earnings ratio is -- while Plus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioAge Labs, Inc. is 118.57x versus 4.41x for Plus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.